In the past week, IPA stock has gone down by -4.56%, with a monthly decline of -17.23% and a quarterly plunge of -35.79%. The volatility ratio for the week is 12.02%, and the volatility levels for the last 30 days are 10.45% for ImmunoPrecise Antibodies Ltd The simple moving average for the past 20 days is -8.25% for IPA’s stock, with a -53.91% simple moving average for the past 200 days.
Is It Worth Investing in ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) Right Now?
The 36-month beta value for IPA is also noteworthy at 0.23. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IPA is 21.81M, and at present, short sellers hold a 0.84% of that float. The average trading volume of IPA on October 24, 2024 was 187.65K shares.
IPA) stock’s latest price update
ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) has experienced a rise in its stock price by 5.58 compared to its previous closing price of 0.51. However, the company has seen a fall of -4.56% in its stock price over the last five trading days. businesswire.com reported 2024-10-21 that VICTORIA, British Columbia–(BUSINESS WIRE)—- $IPA #AI–ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024. AI Driven Drug Discovery Summit Date:.
Analysts’ Opinion of IPA
Many brokerage firms have already submitted their reports for IPA stocks, with H.C. Wainwright repeating the rating for IPA by listing it as a “Buy.” The predicted price for IPA in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on December 02, 2022 of the previous year 2022.
The Benchmark Company, on the other hand, stated in their research note that they expect to see IPA reach a price target of $12. The rating they have provided for IPA stocks is “Buy” according to the report published on October 25th, 2021.
IPA Trading at -20.17% from the 50-Day Moving Average
After a stumble in the market that brought IPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.40% of loss for the given period.
Volatility was left at 10.45%, however, over the last 30 days, the volatility rate increased by 12.02%, as shares sank -21.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.62% lower at present.
During the last 5 trading sessions, IPA fell by -4.56%, which changed the moving average for the period of 200-days by -63.07% in comparison to the 20-day moving average, which settled at $0.5837. In addition, ImmunoPrecise Antibodies Ltd saw -68.68% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IPA
Current profitability levels for the company are sitting at:
- -0.61 for the present operating margin
- 0.48 for the gross margin
The net margin for ImmunoPrecise Antibodies Ltd stands at -1.15. The total capital return value is set at -0.3. Equity return is now at value -62.82, with -40.19 for asset returns.
Based on ImmunoPrecise Antibodies Ltd (IPA), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -0.33. The debt to equity ratio resting at 0.49. The interest coverage ratio of the stock is -913.31.
Currently, EBITDA for the company is -8.0 million with net debt to EBITDA at -1.36. When we switch over and look at the enterprise to sales, we see a ratio of 1.36. The receivables turnover for the company is 6.85for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.99.
Conclusion
In summary, ImmunoPrecise Antibodies Ltd (IPA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
